Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Dexcom (DXCM) EBIT Margin (2016 - 2025)

Dexcom (DXCM) has disclosed EBIT Margin for 16 consecutive years, with 25.64% as the latest value for Q4 2025.

  • On a quarterly basis, EBIT Margin rose 868.0% to 25.64% in Q4 2025 year-over-year; TTM through Dec 2025 was 19.56%, a 468.0% increase, with the full-year FY2025 number at 19.56%, up 468.0% from a year prior.
  • EBIT Margin was 25.64% for Q4 2025 at Dexcom, up from 20.05% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 25.64% in Q4 2025 to a low of 0.09% in Q4 2021.
  • A 5-year average of 14.78% and a median of 15.56% in 2022 define the central range for EBIT Margin.
  • Peak YoY movement for EBIT Margin: tumbled -1819bps in 2021, then soared 1530bps in 2022.
  • Dexcom's EBIT Margin stood at 0.09% in 2021, then soared by 17800bps to 15.38% in 2022, then soared by 36bps to 20.97% in 2023, then decreased by -19bps to 16.96% in 2024, then soared by 51bps to 25.64% in 2025.
  • Per Business Quant, the three most recent readings for DXCM's EBIT Margin are 25.64% (Q4 2025), 20.05% (Q3 2025), and 18.37% (Q2 2025).